Prognostic Value of Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Locally Advanced Nasopharyngeal Carcinoma Authors: JunMei Song, Lan Luo, Ting Liu, YuQing Lv, Qiulin Huang, Rensheng Wang, Jun Bie Published: 2026 ABSTRACT ABSTRACTObjectiveTo investigate the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in patients with locally advanced nasopharyngeal carcinoma (LANPC) receiving concurrent chemoradiotherapy (CCRT), and to clarify its predictive significance for overall survival (OS), progression‐free survival (PFS), locoregional failure‐free survival (LRFFS), and distant metastasis‐free survival (DMFS).MethodsClinical data of 295 patients with LANPC who received CCRT between April 2021 and April 2022 were retrospectively analyzed. Routine blood and biochemical indices were collected within 1 week before CCRT. The HALP score was calculated as follows: HALP = [hemoglobin (g/L) × albumin (g/L) × lymphocytes (109/L)]/platelets (109/L). Patients were divided into high and low HALP groups with the median as the cutoff point. Kaplan–Meier analysis was used to draw survival curves. The log‐rank test was used to compare the survival differences between the high and low HALP groups. Univariate and multivariate Cox regression models were applied to identify independent prognostic factors for patients with LANPC.ResultsSurvival analysis showed that the 3‐year OS of the high and low HALP groups were 95.27% and 93.20%, the 3‐year PFS were 87.84% and 74.15%, and the 3‐year DMFS were 87.84% and 78.91%, respectively. The differences between the groups were statistically significant (p < 0.05). While the 3‐year LRFFS were 97.30% vs. 96.60%, there were no statistically significant differences between the groups. Multivariate Cox regression analysis confirmed that a low HALP score was an independent risk factor for OS and PFS.ConclusionThe HALP group is an effective predictor of prognosis in patients with LANPC. A low HALP group indicated higher disease progression and death. This measurement can be used for prognostic stratification and individualized treatment decision‐making, both simply and economically, and provides a reference for clinical decision‐making and individualized treatment.Keywords: HALP score, locally advanced nasopharyngeal carcinoma, prognostic factors, survival Introduction Nasopharyngeal carcinoma (NPC) is a highly prevalent malignant tumor of the head and neck in southern China and Southeast Asia [1]. It is characterized by strong invasiveness, a high propensity for lymph node metastasis, and a close correlation with the Epstein–Barr virus (EBV) [2]. Approximately 70% of patients present with locally advanced disease at the time of initial diagnosis [3]. Comprehensive treatment based on concurrent chemoradiotherapy (CCRT) significantly improves local control rates; however, treatment failure still occurs in 20%–30% of patients due to distant metastasis or disease progression [4, 5]. These outcomes underscore the importance of identifying new, cost‐effective, and clinically accessible prognostic biomarkers. Currently, the tumor‐node‐metastasis (TNM) staging system is the primary tool for prognostic evaluation in NPC, which reflects the extent of tumor anatomical invasion. However, it is difficult to illustrate the impact of the host condition on prognosis. Patients at the same stage have significant differences in prognosis, highlighting the limitations of the traditional staging system in accurately reflecting the biology of the tumor and predicting individual prognosis. Therefore, more precise prognostic assessment indicators are needed to guide individualized treatment. The nutritional status, immune response, and inflammatory state of the body jointly affect the tumor microenvironment, treatment tolerance, and long‐term survival. Many inflammatory and nutritional prognostic indicators have been developed to predict the survival outcomes of solid tumors, including the neutrophil‐lymphocyte ratio (NLR) [6], lymphocyte‐monocyte ratio (LMR) [7], prognostic nutritional index (PNI) [8], systemic inflammatory index (SII) [9], and albumin‐globulin ratio (AGR) [10]. Among the various emerging prognostic markers, the hemoglobin, albumin, lymphocyte, and platelet (HALP) score stands out as a promising indicator. It assesses the nutritional and inflammatory statuses of patients by combining hemoglobin, albumin, lymphocyte, and platelet counts. Studies have shown that the HALP score has a greater predictive value for the prognosis of patients with cancer than other biomarkers [11, 12]. HALP has been proven to have prognostic predictive value in various malignant tumors such as renal cell carcinoma [13], esophageal cancer [14], gastric cancer [15], non‐small cell lung cancer [16], endometrial cancer [17], colorectal cancer [18], and breast cancer [19]. A previous study explored the prognostic value of HALP in 319 patients with nasopharyngeal, oropharyngeal, and hypopharyngeal cancers and found that HALP was related to survival; however, due to the small sample size, no classification analysis was conducted on the tumors [20]. At present, the prognostic value of the HALP score in locally advanced nasopharyngeal carcinoma (LANPC) remains unclear. This study aimed to investigate the predictive value of the HALP score for the prognosis of patients with LANPC and to analyze its relationship with overall survival (OS), progression‐free survival (PFS), distant metastasis‐free survival (DMFS), and locoregional failure‐free survival (LRFFS). Our goal is to provide a new reference index for the prognosis evaluation and individualized treatment of LANPC. Methods Patients The clinical data of patients with LANPC who received CCRT at the Department of Radiation Oncology of Guangxi Medical University Affiliated First Hospital from April 1, 2021, to April 30, 2022, were retrospectively collected. The inclusion criteria were as follows: pathological diagnosis of NPC; clinical Stage III–IVA (8th edition of the AJCC/UICC staging system); received CCRT; completed routine blood and biochemical tests within 1 week before CCRT; and complete clinical data. The exclusion criteria were history of malignant tumors, concurrent acute infection, hematological diseases, autoimmune diseases, missing data, or loss to follow‐up. Patients for whom survival status could not be verified via outpatient visits, telephone interviews, or medical record systems and for whom no survival outcome records were available as of November 30, 2025, were defined as lost to follow‐up. This study was approved by the Medical Ethics Committee of Guangxi Medical University Affiliated First Hospital. Because the study was retrospective and all data were anonymized, the requirement for written informed consent was waived. Data Collection The clinical data and laboratory indicators of the patients were collected from the hospital's electronic medical record system. Clinical data included age at diagnosis, sex, treatment, smoking history, drinking history, history of hepatitis B, history of diabetes, and history of hypertension. T stage, N stage, TNM stage, height, weight, and Eastern Cooperative Oncology Group (ECOG) score within 1 week before CCRT. Laboratory indicators included hemoglobin (g/L), serum albumin (g/L), lymphocytes (109/L), platelets (109/L), and EBV‐DNA status within 1 week before CCRT. Quantitative detection was adopted for EBV DNA measurement. According to the reference range of EBV DNA levels, patients with EBV‐DNA < 4 × 102 copies were defined as EBV‐DNA negative, whereas those with EBV‐DNA ≥ 4 × 102 copies were defined as EBV‐DNA positive. Treatment All patients underwent intensity‐modulated radiotherapy. The target volume was calibrated according to the 50th and 62nd reports from the International Commission on Radiation Units and Measurements. The prescription dose for the nasopharyngeal primary tumor was 68–74 Gy; metastatic lymph nodes 66–70 Gy; high‐risk prevention area 60–66 Gy; and low‐risk prevention area 50–56 Gy, 30–33 times, five times per week. The concurrent chemotherapy drugs were cisplatin or nedaplatin at a dose of 80–100 mg/m2 every three weeks or 40 mg/m2 once a week. HALP Score Calculation and Grouping The HALP score was calculated as follows: HALP = hemoglobin × serum albumin × lymphocytes/platelets [21]. With the median of HALP as the cut‐off value, the patients were divided into high HALP group (≥ median) and low HALP group (< median). Follow‐Up The follow‐up deadline was November 30, 2025. Follow‐up methods included outpatient review, telephone follow‐up, and review of medical records. The primary endpoints were OS, the time from diagnosis to death from any cause or the last follow‐up; PFS, the time from diagnosis to tumor progression (local recurrence or distant metastasis) or death from any cause; DMFS, the time from diagnosis to the occurrence of distant metastasis or death; and LRFFS, the time from diagnosis to local regional recurrence, death, or the last follow‐up, with the earlier time point being taken. Statistical Analysis Analyses were performed using IBM SPSS Statistics for Windows, version 25.0. Measurement data were expressed as mean ± standard deviation or median (interquartile range), and the t‐test or Mann–Whitney U test was used for comparison between groups. The enumeration data were expressed as frequency (percentage), and the comparison between groups was performed by χ 2 test or Fisher's exact test. The Kaplan–Meier method was used for survival analysis, and the log‐rank test was used for comparisons between groups. The Cox proportional hazards regression model was used for univariate and multivariate analyses, and variables with p < 0.1 in the univariate analysis were included in the multivariate analysis. Statistical significance was set at p < 0.05. Results Baseline Characteristics of Patients A total of 295 patients with LANPC who received CCRT were included in this study (Table 1). Among them, 213 were male (72.20%), and 82 were female (27.80%). There were 260 patients under the age of 60 (88.14%), and 35 patients aged 60 or above (11.86%). One hundred eighteen patients (40%) had Stage III, and 177 patients (60%) had Stage IVa. All patients received CCRT. The median HALP score was 24.83. Patients were divided into the high HALP group (≥ 24.83, n = 148) and low HALP group (< 24.83, n = 147). There were no significant differences in age, T stage, N stage, TNM stage, EBV expression, pathological type, ECOG score, body mass index (BMI), or induction chemotherapy (IC) between the two groups (p > 0.05). Baseline hemoglobin levels were lower in females than in males, which may have led to lower HALP scores in females (Table 1). TABLE 1Comparison of baseline characteristics between high HALP and low HALP group.VariablesTotal patients (n = 295)Low HALP (n = 147)High HALP (n = 148) p Sex0.000* Male213 (72.20%)91 (61.90%)122 (82.43%)Female82 (27.80%)56 (38.10%)26 (17.57%)Age0.101< 60260 (88.14%)125 (85.03%)135 (91.22%)≥ 6035 (11.86%)22 (14.97%)13 (8.78%)T stage0.258T1‐243 (14.58%)18 (12.24%)25 (16.89%)T3‐4252 (85.42%)129 (87.76%)123 (83.11%)N stage0.578N0‐1111 (37.63%)53 (36.05%)58 (39.19%)N2‐3184 (62.37%)94 (63.95%)90 (60.81%)TNM stage a 0.254III118 (40.00%)54 (36.73%)64 (43.24%)IVa177 (60.00%)93 (63.27%)84 (56.76%)Pathological type0.120WHO I–II16 (5.42%)11 (7.48%)5 (3.38%)WHO III279 (94.58%)136 (92.52%)143 (96.62%)Smoking status0.004* No150 (50.85%)87 (59.18%)63 (42.57%)Yes145 (49.15%)60 (40.82%)85 (57.43%)ECOG score0.1810236 (80.00%)113 (76.87%)123 (83.11%)159 (20.00%)34 (23.13%)25 (16.89%)BMI b 0.181Normal145 (49.15%)78 (53.06%)67 (45.27%)Abnormal150 (50.85%)69 (46.94%)81 (54.73%)IC0.494No83 (28.14%)44 (29.93%)39 (26.35%)Yes212 (71.86%)103 (70.07%)109 (73.65%)Hypertension0.982No257 (87.12%)128 (87.07%)129 (87.16%)Yes38 (12.88%)19 (12.93%)19 (12.84%)Diabetes0.564No283 (95.93%)142 (96.60%)141 (95.27%)Yes12 (4.07%)5 (3.40%)7 (4.73%)EB0.092Negative153 (51.86%)69 (46.94%)84 (56.76%)Positive142 (48.14%)78 (53.06%)64 (43.24%)Abbreviations: BMI normal, 18.5–23.9; BMI, body mass index; EB, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; HALP, Hemoglobin, albumin, lymphocyte, platelet score; IC, induction chemotherapy; WHO, World Health Organization.*Statistically significant. a TNM staging followed the 8th edition of the American Joint Commission on Cancer (AJCC) staging system. b BMI was categorized based on Chinese adult criteria: Normal (18.5–23.9 kg/m2) Abnormal (< 18.5 or ≥ 24.0 kg/m2). Comparison of baseline characteristics between high HALP and low HALP group. Abbreviations: BMI normal, 18.5–23.9; BMI, body mass index; EB, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; HALP, Hemoglobin, albumin, lymphocyte, platelet score; IC, induction chemotherapy; WHO, World Health Organization. Statistically significant. TNM staging followed the 8th edition of the American Joint Commission on Cancer (AJCC) staging system. BMI was categorized based on Chinese adult criteria: Normal (18.5–23.9 kg/m2) Abnormal (< 18.5 or ≥ 24.0 kg/m2). Survival Analysis Follow‐up continued until November 30, 2025, with a median follow‐up of 48 months (43–55 months). A total of 29 deaths (9.83%), 65 disease progression events (22.03%), and 55 distant metastasis events (18.64%) occurred. There were 13 local recurrences (4.41%). Kaplan–Meier survival curve showed that the 3‐year OS of the high and low HALP groups was 95.27% and 93.20%; 3‐year PFS 87.84% and 74.15%; 3‐year DMFS 87.84% and 78.91%; and 3‐year LRFFS 97.30% and 96.60%, respectively. The OS, PFS, and DMFS of the low HALP group were significantly lower than those of the high HALP group (all p < 0.05), whereas LRFFS showed no significant difference (p > 0.05) (Figure 1). Kaplan–Meier survival curve of the different ratios of patients with LANPC in the High‐HALP group and the Low‐HALP group. (A) The 3‐year overall survival rates, (B) The 3‐year progression‐free survival rates, (C) The 3‐year distant metastasis‐free survival rates, (D) The 3‐year locoregional failure‐free survival rates. CI, confidence interval; HR, hazard ratio. Univariate and Multivariate Cox Regression Analysis Univariate Cox regression analysis showed that TNM stage (hazard ratio [HR] = 2.628, p = 0.035), IC (HR = 5.516, p = 0.020), EBV (HR = 3.524, p = 0.004), and HALP group (HR = 2.700, p = 0.017) were important factors influencing the prognosis of OS. Multivariate Cox regression analysis showed that EBV stratification and HALP stratification as prognostic factors for OS. No significant interaction was detected between the two variables in interaction testing (F = 2.986, p = 0.085), confirming that low HALP group served as an independent adverse prognostic biomarker for OS in patients with LANPC after adjusting for confounding factors. Low HALP group served as an independent adverse prognostic biomarker for OS in patients with LANPC. Patients with low HALP group had a significantly higher risk of death compared with those with high HALP group (HR = 2.973, p = 0.010) (Table 2). TABLE 2Univariate and multivariate Cox regression analysis for OS.VariableUnivariate analysisMultivariate analysisHR (95% CI) p HR (95% CI) p Sex (male vs. female)1.008 (0.446–2.276)0.985Age (≥ 60 vs. < 60)1.640 (0.626–4.299)0.314Pathological type (I–II vs. III)1.316 (0.313–5.534)0.708T stage (T3‐4 vs. T1‐2)1.522 (0.461–5.030)0.491N stage (N2‐3 vs. N0‐1)1.597 (0.707–3.606)0.260TNM stage (IVa vs. III)2.628 (1.070–6.453)0.035* 1.219 (0.475–3.132)0.680Smoking status (yes vs. no)2.040 (0.949–4.388)0.0682.243 (1.023–4.918)0.044* ECOG score (1 vs. 0)1.557 (0.690–3.515)0.287BMI (abnormal vs. normal)0.889 (0.429–1.841)0.751IC (yes vs. no)5.516 (1.312–23.198)0.020* 4.270 (0.975–18.696)0.054EB (positive vs. negative)3.524 (1.505–8.250)0.004* 2.726 (1.152–6.450)0.022* HALP (low group vs. high group)2.700 (1.196–6.096)0.017* 2.973 (1.297–6.814)0.010* *Statistically significant. Univariate and multivariate Cox regression analysis for OS. Statistically significant. Univariate Cox regression analysis showed that N stage (HR = 2.213, p = 0.007), TNM stage (HR = 1.921, p = 0.019), EBV (HR = 2.902, p = 0.000), and HALP group (HR = 1.851, p = 0.017) were important factors affecting PFS. Multivariate Cox regression analysis showed that EBV stratification and HALP stratification were prognostic factors for PFS. No significant interaction was detected between the two variables in interaction testing (F = 0.561, p = 0.455), confirming that after adjusting for confounding factors, the Low HALP group served as an independent adverse prognostic biomarker for PFS in patients with LANPC. Patients with the low HALP group had a significantly higher risk of disease progression compared with those with the high HALP group (HR = 1.746, p = 0.031) (Table 3). TABLE 3Univariate and multivariate Cox regression analysis for PFS.VariableUnivariate analysisMultivariate analysisHR (95% CI) p HR (95% CI) p Sex (male vs. female)1.004 (0.583–1.729)0.989Age (≥ 60 vs. < 60)1.049 (0.501–2.199)0.899Pathological type (I–II vs. III)0.847 (0.266–2.698)0.779T stage (T3‐4 vs. T1‐2)1.778 (0.768–4.118)0.179N stage (N2‐3 vs. N0‐1)2.213 (1.242–3.941)0.007* 1.756 (0.971–3.174)0.063TNM stage (IVa vs. III)1.921 (1.116–3.307)0.019* 1.284 (0.711–2.318)0.407Smoking status (yes vs. no)1.304 (0.800–2.126)0.288ECOG score (1 vs. 0)1.245 (0.699–2.217)0.457BMI (abnormal vs. normal)1.111 (0.682–1.809)0.673IC (yes vs. no)1.834 (0.980–3.432)0.0581.341 (0.686–2.621)0.391EB (positive vs. negative)2.902 (1.700–4.955)0.000* 2.310 (1.329–4.015)0.003* HALP (low group vs. ≥ high group)1.851 (1.118–3.063)0.017* 1.746 (1.052–2.897)0.031* *Statistically significant. Univariate and multivariate Cox regression analysis for PFS. Statistically significant. Univariate Cox regression analysis showed that N stage (HR = 2.114, p = 0.018), EBV (HR = 3.521, p = 0.000), and HALP group (HR = 1.735, p = 0.047) were important factors affecting DMFS. However, multivariate Cox regression analysis showed that the HALP group was not an independent adverse prognostic biomarker for DMFS in patients with LANPC after adjusting for confounding factors. Patients with a low HALP group had a similar risk of distant metastasis compared with those with a high HALP group (HR = 1.583, p = 0.099) (Table 4). TABLE 4Univariate and multivariate Cox regression analysis for DMFS.VariableUnivariate analysisMultivariate analysisHR (95% CI) p HR (95% CI) p Sex (male vs. female)0.927 (0.518–1.659)0.798Age (≥ 60 vs. < 60)0.578 (0.209–1.600)0.292Pathological type (III vs. I–II)1.023 (0.319–3.276)0.969T stage (T3‐4 vs. T1‐2)1.804 (0.720–4.525)0.208N stage (N2‐3 vs. N0‐1)2.114 (1.134–3.938)0.018* 1.674 (0.882–3.179)0.115TNM stage (IVa vs. III)1.644 (0.928–2.913)0.0891.141 (0.629–2.072)0.664Smoking (yes vs. no)1.089 (0.642–1.848)0.751ECOG (1 vs. 0)1.017 (0.525–1.970)0.959BMI (abnormal vs. normal)1.062 (0.625–1.803)0.824IC (yes vs. no)1.682 (0.869–3.256)0.123EB (positive vs. negative)3.521 (1.919–6.462)0.000* 3.015 (1.610–5.647)0.001* HALP (low group vs. high group)1.735 (1.007–2.990)0.047* 1.583 (0.917–2.734)0.099*Statistically significant. Univariate and multivariate Cox regression analysis for DMFS. Statistically significant. Univariate Cox regression analysis showed that there was no statistical difference in LRFFS between high and low HALP group. According to the statistical strategy of prognostic research, multivariate Cox regression was not constructed for this endpoint, and no corrected HR data was obtained (Table 5). TABLE 5Univariate and multivariate Cox regression analysis for LRFFS.VariableUnivariate analysisMultivariate analysisHR (95% CI) p HR (95% CI) p Sex (male vs. female)4.673 (0.608–35.938)0.139Age (≥ 60 vs. < 60)1.396 (0.309–6.300)0.664Pathological type (III vs. I–II)0.046 (0.000–1672.838)0.565T stage (T3‐4 vs. T1‐2)2.113 (0.275–16.252)0.472N stage (N2‐3 vs. N0‐1)2.052 (0.565–7.456)0.275TNM stage (IVa vs. III)1.088 (0.356–3.325)0.883Smoking (yes vs. no)5.930 (1.314–26.756)0.021* 5.649 (1.251–25.509)0.024ECOG (1 vs. 0)0.738 (0.164–3.329)0.693BMI (abnormal vs. normal)3.223 (0.887–11.711)0.0753.004 (0.826–10.922)0.095IC (yes vs. no)1.319 (0.363–4.794)0.674EB (positive vs. negative)0.948 (0.318–2.821)0.923HALP (low group vs. high group)0.882 (0.296–2.625)0.822*Statistically significant. Univariate and multivariate Cox regression analysis for LRFFS. Statistically significant. Based on the multivariate Cox regression correction model, we extracted the adjusted HR and 95% confidence interval corresponding to HALP, and plotted forest map to show the effect values of OS, PFS and DMFS. The independent predictive value of HALP for different survival endpoints after adjusting for confounding factors suggested that HALP was an independent prognostic factor for PFS and OS after excluding confounding factors (Figure 2). Risk ratio forest map of HALP group predicting OS, PFS, and DMFS after adjusting confounding factors based on COX regression analysis. Discussion Accurately predicting the survival outcomes of patients with cancer is crucial for providing personalized treatment. Therefore, it is important to identify new biomarkers to predict survival outcomes. This study is the first to systematically evaluate the prognostic value of the HALP group in patients with LANPC undergoing CCRT. The results showed that the 3‐year OS, PFS, and DMFS of patients with low HALP group were lower than those with high HALP group. The 3‐year OS, PFS, and DMFS of the high HALP group and the low HALP group were 95.27% versus 93.20%, 87.84% versus 74.15%, and 87.84% versus 78.91%, respectively. The difference was statistically significant (p < 0.05). The 3‐year LRFFS of the high HALP group and the low HALP group was 97.30% versus 96.60%, and the difference was not statistically significant (p > 0.05). Confirming that after adjusting for confounding factors after excluding the interference of confounding factors, the low HALP group served as an independent adverse prognostic biomarker for PFS and OS in patients with LANPC. The 3‐year OS rates were 95.27% and 93.20% in the high and low HALP groups, respectively, with an absolute difference of merely 2.07%. The marginal numerical discrepancy in short‐term survival indicates that relying solely on the single 3‐year follow‐up time point cannot intuitively reflect the prognostic stratification efficacy of HALP. This phenomenon is attributable to the generally favorable OS of patients with LANPC and the limited number of death events within the first 3 years of follow‐up. Despite the narrow gap in short‐term survival rates, multivariate adjusted analyses revealed that patients in the low HALP group exhibited a significantly elevated risk of mortality. Moreover, the separation between Kaplan–Meier survival curves gradually widened with prolonged follow‐up, and the cumulative survival disadvantage became more pronounced over the long term (HR = 2.973, 95% CI 1.297–6.814, p < 0.05), suggesting that HALP serves as an independent and persistently effective prognostic biomarker. For lANPC with generally good OS, a small difference in short‐term survival rate combined with an increased long‐term cumulative risk still has the value of stratified guidance for clinical management. These findings suggest that the HALP group can effectively supplement the deficiency of TNM anatomical staging, identify subgroups with the same stage but different prognoses in traditional staging, and address the heterogeneity problem of LANPC prognosis. Because HALP is derived from routine laboratory tests and is easy to implement in clinical practice, it represents a low‐cost and widely accessible biomarker. Although the short‐term survival difference of HALP is limited, it can still be used as a baseline stratification tool to screen high‐risk patients and guide clinical follow‐up and individualized intervention. At the same time, HALP has a more significant effect on the differentiation of PFS in this study. In clinical work, multiple survival endpoints can be combined to comprehensively evaluate the prognostic risk of patients. Therefore, this study provides a simple and accessible new basis for the precise risk stratification and individualized treatment of patients with LANPC. The mechanism underlying the role of HALP score in tumor prognosis has not been extensively studied. It is speculated that the HALP score can predict prognosis because this index integrates four indicators: hemoglobin, albumin, lymphocytes, and platelets. Compared to a single index, the HALP score provides a more comprehensive assessment of the nutritional and immune status of patients with tumors. Hemoglobin reflects oxygen‐carrying capacity and anemia status. Low hemoglobin is associated with tumor hypoxia, angiogenesis, and radiochemotherapy resistance [22]. Albumin is a core indicator of nutrition and serum albumin is an alternative marker of systemic inflammation and nutritional reserves. Low albumin levels can impair lymphocyte proliferation, antigen presentation, and cytokine production, thereby weakening immune surveillance and promoting immune evasion. In addition, hypoproteinemia is associated with increased oxidative stress and endothelial dysfunction, which further promote tumor growth and metastasis [23]. Lymphocyte count represents the level of anti‐tumor immunity, and an increase in platelet count reflects a pro‐inflammatory and pro‐thrombotic state. Platelets promote tumor growth and metastasis by regulating immune escape, angiogenesis, homing, and exudation [24]. By combining these factors, the HALP score reflects tumor‐induced malnutrition, systemic inflammation, immunosuppression, and hematological exhaustion, all of which drive cancer progression and lead to treatment resistance [25]. Impaired immune nutritional status in patients with cancer may lead to delayed wound healing, poor tolerance and responsiveness to chemotherapy, higher complication rates, longer hospital stays, and poorer prognosis [26, 27]. Therefore, the HALP score provides an overall assessment of a patient's condition, making it a valuable tool for predicting the prognosis of LANPC. Previous studies have confirmed that the HALP score has a prognostic predictive value in various solid tumors. Peng et al. [28] found that low HALP scores were an independent prognostic factor for tumor‐specific survival after nephrectomy in patients with renal cell carcinoma. Chen et al. [29] found that in patients with gastric cancer, the median survival time and 1‐, 2‐, and 3‐year OS in the high HALP group were higher than those in the low HALP group. Zhao et al. [30] found that the HALP score was an independent factor affecting the prognosis of NPC, which is consistent with our results. However, the patients with NPC included in this study were T3‐4N0‐1 patients, and only the predictive value of HALP for OS was analyzed. A meta‐analysis of 13,038 patients showed that low HALP scores were associated with decreased OS in patients with solid tumors [31]. Duzkopru et al. [32] found that HALP and PNI scores were prognostic factors in patients with metastatic head and neck cancer. Wu et al. found that the HALP score was an independent prognostic factor for pharyngeal cancer [20]. Our study further verified the applicability of the HALP score in NPC, a high‐incidence tumor in China, and enriched its evidence chain in head and neck tumors, suggesting that nutritional improvement, anemia correction, immune regulation, and control of abnormal platelet elevation may be transformed into survival benefits, providing a basis for intervention targets. The HALP cutoff value varies greatly in different studies [33]. The study reported that the maximum cut‐off value of HALP was 56.89 [29], and the minimum cut‐off value was 0.277 [13]. Different studies have different ways to obtain the cut‐off value of HALP. Some use X‐tile [34], some use ROC curve [35], some use median [36], and some refer to other study [17]. The reason why HALP cut‐off values vary greatly in different studies is that there are different ways to obtain HALP cut‐off values, and it is affected by tumor type, stage, race, laboratory test standards, and treatment regimens. The cut‐off value of HLAP in our study is close to the cut‐off value of Shen [37], Njoku [17]. However, this study has several limitations. First, it was a single‐center retrospective study, which may introduce selection bias. Second, the sample size was limited, highlighting the need for multicenter, large‐sample studies for validation. Furthermore, a single unified HALP cut‐off value derived from the entire cohort was applied in this study without gender‐specific thresholds, which may introduce gender‐related confounding bias. In addition, direct exclusion of patients lost to follow‐up may eliminate a subset of patients with poor long‐term prognosis, thereby carrying a risk of underestimating the incidence of adverse events. The absence of systematic records for missing data represents another limitation of the present work. In future research, we plan to conduct large‐scale multicenter prospective cohort studies to establish gender‐stratified HALP cut‐off criteria, standardize follow‐up protocols to reduce loss‐to‐follow‐up rates, and perform statistical analyses using censoring methods to minimize bias, so as to further improve the clinical practicability of this marker. Conclusions This study demonstrated the HALP score as a prognostic predictor in patients with LANPC. Lower HALP scores were associated with poorer OS and PFS. These findings indicate that the HALP score is easy to calculate, cost‐effective, accessible, and can effectively stratify prognoses. It can be used as an important reference for prognostic evaluation and individualized treatment decision‐making in patients with LANPC. Author Contributions Lan Luo: data curation, writing – original draft. Rensheng Wang: conceptualization, supervision, methodology. Ting Liu: data curation, investigation. YuQing Lv: data curation, investigation. Jun Bie: conceptualization, funding acquisition, supervision, methodology. JunMei Song: data curation, funding acquisition, writing – original draft, writing – review and editing. Qiulin Huang: data curation, investigation. Funding This study was supported by grants from the Project of Bureau of Science & Technology Nanchong City (20SXQT0257), Major Project of Sichuan Science and Technology Department (2023YFS0473). Ethics Statement The study was approved by the research ethics committee (approval number: 2026‐E0291, approval date: April 1, 2026). Informed consent was waived by our Institutional Review Committee due to the retrospective nature of our study. Conflicts of Interest The authors declare no conflicts of interest. Contributor Information Rensheng Wang, Email: rs13807806008@163.com. Jun Bie, Email: 78593860@qq.com. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.